CompletedNot Applicable

ALN OATF Vena Cava Filter

France50 participantsStarted 2023-02-14

Plain-language summary

Migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (PE). It can be prevented mechanically by implanting a vena cava filter (VCF) in the inferior vena cava. The implation of a VCF is indicated for patients with acute PE and a contraindication to anticoagulation, with an acute deep vein thrombosis (DVT) without PE and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation. The purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional ALN OATF VCF in current practice.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient implanted with an ALN OATF VCF * Patient informed Exclusion Criteria: * Minor patient * Adult patient under a legal protection measure * Pregnant, parturient or breastfeeding women * Patient who refused to participate * Patient who cannot or does not wish to be followed by the Interventional Radiology Department

What they're measuring

Filter implantation

Timeframe: day 0

Trial details

NCT IDNCT05785676

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-31

View on ClinicalTrials.gov More Pulmonary Embolism trials